Press Release TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update 6 hours ago
Press Release TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies Jul 29